Ipratropium/Albuterol Sulfate
Brand name: Combivent Respimat
Rank #151 of 500 drugs by total cost
$108.3M
Total Cost
353,594
Total Claims
$108.3M
Total Cost
13,193
Prescribers
$306
Cost per Claim
67,069
Beneficiaries
392,314
30-Day Fills
$8,212
Avg Cost/Provider
27
Avg Claims/Provider
About Ipratropium/Albuterol Sulfate
Ipratropium/Albuterol Sulfate (sold as Combivent Respimat) was prescribed 353,594 times by 13,193 Medicare Part D providers in 2023, costing the program $108.3M. At $306 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 148 | Immun Glob G(Igg)/Gly/Iga 0-50 (Gammaplex) | $109.6M | 7,815 |
| 149 | Mesalamine (Mesalamine) | $109.3M | 176,079 |
| 150 | Axitinib (Inlyta) | $109.1M | 5,937 |
| 151 | Ipratropium/Albuterol Sulfate (Combivent Respimat) | $108.3M | 353,594 |
| 152 | Relugolix (Orgovyx) | $107.3M | 38,821 |
| 153 | Pen Needle, Diabetic (Ultra-Fine Mini Pen Needle) | $105.0M | 1,305,150 |
| 154 | Divalproex Sodium (Divalproex Sodium) | $103.4M | 1,921,840 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology